Abstract
The POPADAD (Prevention Of Progression of Arterial Disease And Diabetes) study did not show a benefit for low-dose aspirin therapy or administration of antioxidants for the primary prevention of cardiovascular disease events in individuals with diabetes and asymptomatic peripheral arterial disease. Although low-dose aspirin continues to be recommended in international guidelines, no convincing trial-based evidence exists that supports its routine use for primary prevention of cardiovascular disease in people with diabetes. This paradox is unhelpful and the guidelines should be relaxed until definitive evidence becomes available.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
American Diabetes Association (2007) Standards of medical care in diabetes—2007. Diabetes Care 30 (Suppl 1): S4–S41
Nicolucci A et al. (2007) AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions. Eur Heart J 28: 1925–1927
Belch J et al. (2008) The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 337: a1840
Antithrombotic Trialists' Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324: 71–86
Ogawa H et al. (2008) Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 300: 2134–2141
Natarajan A et al. (2008) Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents. Diab Vasc Dis Res 5: 138–144
ETDRS Investigators (1992) Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. JAMA 268: 1292–1300
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
RR Holman has received research support from Bayer. HC Price declared no competing interests.
Rights and permissions
About this article
Cite this article
Price, H., Holman, R. Primary prevention of cardiovascular events in diabetes: is there a role for aspirin?. Nat Rev Cardiol 6, 168–169 (2009). https://doi.org/10.1038/ncpcardio1446
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpcardio1446